Emprumapimod

Emprumapimod (PF-07265803) is a potent, orally active and selective inhibitor of p38α MAPK directly inhibits LPS-induced IL-6 production from RPMI-8226 cell (IC50=100 pM) . Emprumapimod can be used for the research of dilated cardiomyopathy and acute inflammatory pain[1][2].

Product Specifications

CAS Number

[765914-60-1]

Product Name Alternative

PF-07265803

UNSPSC

12352005

Target

P38 MAPK

Type

Reference compound

Related Pathways

MAPK/ERK Pathway

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/emprumapimod.html

Purity

99.12

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(C)CN1C2=CC(C(N[C@H](C(N)=O)CCN(C)C)=O)=C(OC3=C(C=C(C=C3)F)F)C=C2C=N1

Molecular Formula

C24H29F2N5O3

Molecular Weight

473.52

References & Citations

[1]Dale Wright, et al. ARRY-797, a Potent and Selective Inhibitor of p38 Map Kinase, Inhibits LPS-Induced IL-6 and In Vivo Growth of RPMI-8226 Human Multiple Myeloma Cells.|[2]Antoine Muchir, et al. Abnormal p38α mitogen-activated protein kinase signaling in dilated cardiomyopathy caused by lamin A/C gene mutation. Hum Mol Genet. 2012 Oct 1;21 (19) :4325-33.